Withers H Rodney, Lee Steve P
Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Semin Radiat Oncol. 2006 Apr;16(2):111-9. doi: 10.1016/j.semradonc.2005.12.006.
The kinetics of development of micrometastases, and especially of small numbers of metastases (oligometastases), was explored by using simple assumptions to develop concepts that may be useful for framing future research. The conclusions depend on the assumptions and hence must be considered speculative. It is assumed that beyond a threshold size for initiation of metastatic spread, which varies widely from tumor to tumor, the rate at which a primary tumor sheds new metastases increases exponentially, in parallel with its exponential growth. This increasing rate of release of new metastatic clonogens from the primary tumor is accompanied by a similar exponential growth of each of the micrometastases newly established at a secondary site. This creates a log-log linear relationship between the volume distribution of metastases and number of metastases, there being one largest metastasis followed by an exponentially expanding number of logarithmically smaller micrometastases. For example, if the micrometastases and the primary tumor grew at the same rate for 6 doublings after initiation of the first metastasis, then the primary tumor would have increased its volume by a factor of 64 (2(6)) and would be shedding metastatic clonogens at 64 times the initial rate. The first metastasis would undergo 6 doublings and contain 64 cells; the succeeding 2 metastases, released as the primary doubled in volume, would undergo 5 doublings and each would contain 32 cells; and so forth down to the 64 most recently developed single-cell metastases. However, the growth rate of metastases is expected to be faster than that of the primary tumor so that the rate of increase in volume of the micrometastases would be faster than the rate of increase in their numbers (through release of new metastases from the primary). Thus, although the log-log linear relationship is maintained, the slope of the volume frequency curve is changed; if the micrometastases grew 5 times faster than the primary, the slope would change by a factor of 5. Removal of the primary tumor as a source of new metastases truncates the expansion in numbers of metastases without affecting the growth rate of existing micrometastases, with the result that the volume-frequency relationship is maintained but the whole curve is shifted to larger volumes as micrometastases grow toward clinical detectability. The development of an oligometastatic distribution requires that the exponential expansion in the number of new metastases be stopped by eliminating the primary tumor soon after the first metastasis is shed. A cell destined to become part of an oligometastatic distribution had just been newly deposited at its metastatic site at the time the primary tumor was removed and must undergo about 30 doublings to become clinically detectable as an overt metastasis (2(30) or 10(9) cells). Thus, the time interval between removal of the primary and subsequent appearance of oligometastases will be toward the upper end of a distribution of "metastasis-free" intervals for its particular class of tumor. The actual time to appearance of a solitary metastasis, or of oligometastases, in any particular patient will depend on the growth rate of the metastases in that individual but will always require about 30 volume doublings. An apparently solitary metastasis appearing synchronously with the primary tumor is unlikely to be solitary because, to do so, it would have to have undergone about 30 doublings without further release of metastatic clonogens from the primary that is, in our model, within 1 doubling in volume of the primary tumor. For the same reason, a synchronous or early appearing oligometastatic distribution is unlikely, but if it were to exist, there would be a steep gradient between the volumes of largest and smallest metastases because the growth rate of the micrometastases to produce synchronous metastases, without having further metastases shed from the primary, would have to be fast (up to 30x) relative to the growth rate of the primary. Conversely, a steep gradient in volumes of successive echelons of metastases reflects fast growth of metastases relative to the primary and favors the possibility of an oligometastatic distribution. This ratio of growth rates of metastases to primary is defined by the slope of the log-log curve for the volume-frequency distribution of metastases, which, in clinical practice, is difficult to determine over a wide range and is, by definition, essentially impossible for oligometastases. However, the volume-frequency relationship, measured over a wide range, is the same as the ratio of the volume of the largest to second-largest metastases in an oligometastatic situation. For example, if the metastasis doubled 5 times faster than the primary, the largest metastasis would be larger by 5 doublings than its closest follower(s), that is, by a factor of 2(5) or 32, equivalent to a 3.2-fold difference in diameter if the metastases were spherical. Alternatively, if an initially solitary and measurable metastasis is subsequently joined by measurable followers, the number of volume doublings separating successive echelons in the series can be determined directly, and the larger the difference (measured in doublings), the greater the probability that there will be a limited, oligometastatic condition (ie, in clinical terms, subsequent metastases will stop appearing after the large leader metastasis and a short succession of followers have been removed at 1 or more operations). In summary, the probability of there being an oligometastatic distribution is increased as the interval between removal of the primary tumor and appearance of metastases lengthens. It is also more likely the faster the metastases are growing relative to the growth rate of the primary tumor before its removal. Effective systemic cytotoxic treatment (eg, chemotherapy, hormonal manipulation, biological agents) given in the perioperative period, or concomitantly with radiation therapy for the primary tumor, would truncate the volume-frequency distribution toward an oligometastatic one by eliminating the smallest, most recently formed "tail-ender" metastases. That process, which only occurs at the threshold volume of the primary at which metastases are first initiated, would not be influenced by whether surgery or radiation therapy was chosen to treat the primary tumor, regardless of the overall duration of radiation therapy. Chemotherapy adjuvant to surgery is not usually indicated in the curative treatment of solitary or oligometastases because they represent a truncated distribution with few or no stragglers. If subclinical stragglers exist, they would usually be relatively large and, even though subclinical, too large to be cured by chemotherapy. Exceptions would be early rapidly growing oligometastases, especially from a slowly growing primary, or solitary metastases from an unknown primary where second echelon metastases, if they exist, may still be small. Otherwise chemotherapy could be postponed and used for palliative growth restraint of unusually large and/or numerous stragglers.
通过采用简单假设来构建一些概念,对微转移灶尤其是少量转移灶(寡转移灶)的发展动力学进行了探索,这些概念可能有助于规划未来的研究。结论取决于假设,因此必须视为推测性的。假设在启动转移扩散的阈值大小之上(该阈值因肿瘤而异),原发肿瘤产生新转移灶的速率呈指数增长,与其指数生长并行。原发肿瘤释放新的转移克隆原的速率增加,同时在继发部位新形成的每个微转移灶也有类似的指数生长。这在转移灶的体积分布和转移灶数量之间建立了对数 - 对数线性关系,即有一个最大的转移灶,随后是数量呈指数增长的对数级更小的微转移灶。例如,如果在第一个转移灶出现后,微转移灶和原发肿瘤以相同速率生长6次倍增,那么原发肿瘤的体积将增加64倍(2(6)),并且释放转移克隆原的速率将是初始速率的64倍。第一个转移灶将经历6次倍增并包含64个细胞;随着原发肿瘤体积翻倍而释放的接下来2个转移灶,将经历5次倍增,每个将包含32个细胞;以此类推,直到最近形成的64个单细胞转移灶。然而,预计转移灶的生长速率比原发肿瘤快,因此微转移灶体积的增加速率将比其数量的增加速率快(通过原发肿瘤释放新的转移灶)。因此,尽管对数 - 对数线性关系得以维持,但体积频率曲线的斜率会发生变化;如果微转移灶的生长速度比原发肿瘤快5倍,斜率将变化5倍。去除作为新转移灶来源的原发肿瘤会截断转移灶数量的增长,而不影响现有微转移灶的生长速率,结果是体积 - 频率关系得以维持,但随着微转移灶生长至临床可检测性,整个曲线会向更大体积偏移。寡转移分布的形成要求在第一个转移灶脱落之后不久通过消除原发肿瘤来停止新转移灶数量的指数增长。一个注定要成为寡转移分布一部分的细胞,在原发肿瘤被切除时刚刚新沉积在其转移部位,并且必须经历大约30次倍增才能作为明显的转移灶在临床上被检测到(2(30)或10(9)个细胞)。因此,切除原发肿瘤与随后出现寡转移灶之间的时间间隔将处于其特定类型肿瘤的“无转移”间隔分布的上限。在任何特定患者中,出现孤立转移灶或寡转移灶的实际时间将取决于该个体中转移灶的生长速率,但总是需要大约30次体积倍增。与原发肿瘤同时出现的明显孤立转移灶不太可能是孤立的,因为要做到这一点,它必须在没有原发肿瘤进一步释放转移克隆原的情况下经历大约30次倍增,即在我们的模型中,在原发肿瘤体积增加1倍的范围内。出于同样的原因,同步或早期出现的寡转移分布不太可能,但如果存在,最大和最小转移灶的体积之间会有陡峭的梯度,因为在没有原发肿瘤进一步释放转移灶的情况下产生同步转移灶的微转移灶的生长速率相对于原发肿瘤必须很快(高达30倍)。相反,连续梯队的转移灶体积的陡峭梯度反映了转移灶相对于原发肿瘤的快速生长,并有利于寡转移分布的可能性。转移灶与原发肿瘤的生长速率之比由转移灶体积 - 频率分布的对数 - 对数曲线的斜率定义,在临床实践中,很难在很宽的范围内确定,并且根据定义,对于寡转移灶基本上是不可能的。然而,在很宽范围内测量的体积 - 频率关系与寡转移情况下最大转移灶与第二大转移灶的体积之比相同。例如,如果转移灶的倍增速度比原发肿瘤快5倍,最大的转移灶将比其最接近的后续转移灶大5次倍增,即大2(5)或32倍,如果转移灶是球形的,直径相差3.2倍。或者,如果最初孤立且可测量的转移灶随后有可测量的后续转移灶出现,可以直接确定该系列中连续梯队之间的体积倍增次数,差异越大(以倍增次数衡量),出现有限的寡转移情况的可能性就越大(即,从临床角度来看,在切除大的主导转移灶和1次或更多次手术中切除的一小串后续转移灶之后,后续转移灶将停止出现)。总之,随着切除原发肿瘤与转移灶出现之间的时间间隔延长,出现寡转移分布的可能性增加。转移灶相对于切除原发肿瘤之前原发肿瘤的生长速率越快,这种可能性也越大。围手术期给予有效的全身细胞毒性治疗(例如化疗、激素治疗、生物制剂),或与原发肿瘤的放射治疗同时给予,将通过消除最小、最新形成的“末端”转移灶使体积 - 频率分布向寡转移分布截断。这个过程仅发生在原发肿瘤开始转移的阈值体积时,无论选择手术还是放射治疗来治疗原发肿瘤,都不会受到影响,无论放射治疗的总持续时间如何。手术辅助化疗通常不适用于孤立或寡转移灶的根治性治疗,因为它们代表一种截断的分布,几乎没有或没有零散的转移灶。如果存在亚临床零散转移灶,它们通常相对较大,即使是亚临床的,也太大而无法通过化疗治愈。例外情况是早期快速生长的寡转移灶,特别是来自生长缓慢的原发肿瘤,或者来自未知原发肿瘤的孤立转移灶,如果存在二级转移灶,可能仍然较小。否则,可以推迟化疗,并用于对异常大的和/或大量零散转移灶进行姑息性生长抑制。